Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2019

01-01-2019 | Original Article

FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging

Authors: A. P. Douglas, K. A. Thursky, L. J. Worth, E. Drummond, A. Hogg, R. J. Hicks, M. A. Slavin

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2019

Login to get access

Abstract

Purpose

Invasive fungal infections (IFIs) are common in immunocompromised patients. While early diagnosis can reduce otherwise high morbidity and mortality, conventional CT has suboptimal sensitivity and specificity. Small studies have suggested that the use of FDG PET/CT may improve the ability to detect IFI. The objective of this study was to describe the proven and probable IFIs detected on FDG PET/CT at our centre and compare the performance with that of CT for localization of infection, dissemination and response to therapy.

Methods

FDG PET/CT reports for adults investigated at Peter MacCallum Cancer Centre were searched using keywords suggestive of fungal infection. Chart review was performed to describe the risk factors, type and location of IFIs, indication for FDG PET/CT, and comparison with CT for the detection of infection, and its dissemination and response to treatment.

Results

Between 2007 and 2017, 45 patients had 48 proven/probable IFIs diagnosed prior to or following FDG PET/CT. Overall 96% had a known malignancy with 78% being haematological. FDG PET/CT located clinically occult infection or dissemination to another organ in 40% and 38% of IFI patients, respectively. Of 40 patients who had both FDG PET/CT and CT, sites of IFI dissemination were detected in 35% and 5%, respectively (p < 0.001). Of 18 patents who had both FDG PET/CT and CT follow-up imaging, there were discordant findings between the two imaging modalities in 11 (61%), in whom normalization of FDG avidity of a lesion suggested resolution of active infection despite a residual lesion on CT.

Conclusion

FDG PET/CT was able to localize clinically occult infection and dissemination and was particularly helpful in demonstrating response to antifungal therapy.
Appendix
Available only for authorised users
Literature
1.
Tang JL, Kung HC, Lei WC, Yao M, Wu UI, Hsu SC, et al. High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan. PLoS One. 2015;10(6):e0128410.CrossRef
2.
Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.PubMed
3.
Shi JM, Pei XY, Luo Y, Tan YM, Tie RX, He JS, et al. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. J Zhejiang Univ Sci B. 2015;16(9):796–804.CrossRef
4.
Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634–41.CrossRef
5.
Teng JC, Slavin MA, Teh BW, Lingaratnam SM, Ananda-Rajah MR, Worth LJ, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462–6.CrossRef
6.
Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, et al. Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 2015;100(1):e28–31.CrossRef
7.
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.CrossRef
8.
Horn DL, Freifeld AG, Schuster MG, Azie NE, Franks B, Kauffman CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance® registry. Mycoses. 2014;57(11):652–8.CrossRef
9.
Nucci M, Marr KA, Vehreschild MJGT, de Souza CA, Velasco E, Cappellano P, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–5.CrossRef
10.
Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.CrossRef
11.
Rolfe NE, Sandin RL, Greene JN. Scedosporium infections at a Cancer Centre over a 10-year period (2001-2010). Infect Dis Clin Pract. 2014;22(2):71–4.CrossRef
12.
Farmakiotis D, Kyvernitakis A, Tarrand JJ, Kontoyiannis DP. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect. 2015;21(1):79–86.CrossRef
13.
Gafter-Gvili A, Paul M, Bernstine H, Vidal L, Ram R, Raanani P, et al. The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. Leuk Res. 2013;37(9):1057–62.CrossRef
14.
Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis. 2013;13(6):519–28.CrossRef
15.
Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139(4):519–31.CrossRef
16.
Douglas A, Lau E, Thursky K, Slavin M. What, where and why: exploring fluorodeoxyglucose-PET’s ability to localise and differentiate infection from cancer. Curr Opin Infect Dis. 2017;30(6):552–64.CrossRef
17.
Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17(3):409–17.CrossRef
18.
Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Med Mycol. 2008;46(1):23–9.CrossRef
19.
Vos FJ, Donnelly JP, Oyen WJG, Kullberg BJ, Bleeker-Rovers CP, Blijlevens NMA. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39(1):120–8.CrossRef
20.
Guy SD, Tramontana AR, Worth LJ, Lau E, Hicks RJ, Seymour JF, et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging. 2012;39(8):1348–55.CrossRef
21.
Koh KC, Slavin MA, Thursky KA, Lau E, Hicks RJ, Drummond E, et al. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. Leuk Lymphoma. 2012;53(10):1889–95.CrossRef
22.
Mahfouz T, Miceli MH, Saghafifar F, Stroud S, Jones-Jackson L, Walker R, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23(31):7857–63.CrossRef
23.
Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16(1):35.CrossRef
24.
Miyazaki Y, Nawa Y, Nakase K, Kohashi S, Kadohisa S, Hiraoka A, et al. FDG-PET can evaluate the treatment for fungal liver abscess much earlier than other imagings. Ann Hematol. 2011;90(12):1489–90.CrossRef
25.
Xu B, Shi P, Wu H, Guo X, Wang Q, Zhou S. Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis. Clin Nucl Med. 2010;35(8):567–70.CrossRef
26.
Wang C, Jia N, Zhang L, Liu K, Liu H, Yu H. Imaging findings of cryptococcal infection of the thoracic spine. Int J Infect Dis. 2014;29:162–5.CrossRef
27.
Altini C, Niccoli Asabella A, Ferrari C, Rubini D, Dicuonzo F, Rubini G. (18)F-FDG PET/CT contribution to diagnosis and treatment response of rhino-orbital-cerebral mucormycosis. Hell J Nucl Med. 2015;18(1):68–70.PubMed
28.
Muller N, Kessler R, Caillard S, Epailly E, Hubele F, Heimburger C, et al. 18F-FDG PET/CT for the diagnosis of malignant and infectious complications after solid organ transplantation. Nucl Med Mol Imaging. 2017;51(1):58–68.CrossRef
29.
Karunanithi S, Kumar G, Sharma SK, Jain D, Gupta A, Kumar R. Staging and response of sternal histoplasmosis by 18F-FDG PET/CT. Clin Nucl Med. 2015;40(3):231–3.CrossRef
30.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.CrossRef
31.
Avet J Jr, Granjon D, Prevot-Bitot N, Isnardi V, Berger C, Stephan JL, et al. Monitoring of systemic candidiasis by 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(11):1900.CrossRef
32.
Bleeker-Rovers CP, Warris A, Drenth JPH, Corstens FHM, Oyen WJG, Kullberg BJ. Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Infect. 2005;11(6):493–5.CrossRef
33.
Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg. 2006;82(3):1016–20.CrossRef
Metadata
Title
FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging
Authors
A. P. Douglas
K. A. Thursky
L. J. Worth
E. Drummond
A. Hogg
R. J. Hicks
M. A. Slavin
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4062-8

Other articles of this Issue 1/2019

European Journal of Nuclear Medicine and Molecular Imaging 1/2019 Go to the issue

Original Article

Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma

Review Article

Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements

Original Article

18F-FDGPET/CT in fever of unknown origin and inflammation of unknown origin: a Chinese multi-center study

Original Article

Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

Book Review

C.R. Goldfarb, M. Chamarthy, F. Ongseng, S.R. Parmett, D.L. Bushnell, R. Mirtcheva-Trocheva, U. Sen, L.S. Zuckier. Nuclear Medicine Board Review: Questions and answers for self-assessment, 4th Edition

Editorial Commentary

FDG-PET imaging to detect and characterize underlying causes of fever of unknown origin: an unavoidable path for the foreseeable future